The Latest

Health Canada approves Novavax COVID-19 vaccine targeting XBB.1.5 variant

Abdur Rahman Khan

Health Canada has authorized a new COVID-19 vaccine from Novavax that targets the XBB.1.5 variant.

Health Canada has authorized a new COVID-19 vaccine from Novavax that targets the XBB.1.5 variant. The new vaccine is called Nuvaxovid and is approved for people 12 years of age and over.

Nuvaxovid is a protein subunit vaccine, meaning it contains harmless pieces of virus. This is in contrast to the two other XBB vaccines currently authorized in Canada, which are mRNA vaccines. mRNA vaccines work by instructing the body’s cells to make copies of a harmless piece of virus material, which then triggers an immune response.

The National Advisory Committee on Immunization (NACI) recommends that everyone six months of age and older get the XBB.1.5 vaccine if it has been six months or longer since their last COVID-19 vaccination or COVID-19 infection.

Related Articles

Back to top button